title: Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax.
abstract: BACKGROUND
  Bacillus anthracis, the etiologic agent of inhalational anthrax, is a facultative intracellular pathogen. Despite appropriate antimicrobial therapy, the mortality from inhalational anthrax approaches 45%, underscoring the need for better adjuvant therapies. The variable latency between exposure and development of disease suggests an important role for the host's innate immune response. Type I and Type II Interferons (IFN) are prominent members of the host innate immune response and are required for control of intracellular pathogens. We have previously described a protective role for exogenous Type I and Type II IFNs in attenuating intracellular B.anthracis germination and macrophage cell death in vitro.
  
  
  RESULTS
  We sought to extend these findings in an in vivo model of inhalational anthrax, utilizing the Sterne strain (34F2) of B.anthracis. Mice devoid of STAT1, a component of IFN-alpha and IFN-gamma signaling, had a trend towards increased mortality, bacterial germination and extrapulmonary spread of B.anthracis at 24 hrs. This was associated with impaired IL-6, IL-10 and IL-12 production. However, administration of exogenous IFN-gamma, and to a lesser extent IFN-alpha, at the time of infection, markedly increased lethality. While IFNs were able to reduce the fraction of germinated spores within the lung, they increased both the local and systemic inflammatory response manifest by increases in IL-12 and reductions in IL-10. This was associated with an increase in extrapulmonary dissemination. The mechanism of IFN mediated inflammation appears to be in part due to STAT1 independent signaling.
  
  
  CONCLUSIONS
  In conclusion, while endogenous IFNs are essential for control of B.anthracis germination and lethality, administration of exogenous IFNs appear to increase the local inflammatory response, thereby increasing mortality.
authors: Division of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon, United States of America. goldje@ohsu.edu
authors: Jeffrey A
authors: JA
authors: Gold
authors: Yoshihiko
authors: Y
authors: Hoshino
authors: Marcus B
authors: MB
authors: Jones
authors: Satomi
authors: S
authors: Hoshino
authors: Anna
authors: A
authors: Nolan
authors: Michael D
authors: MD
authors: Weiden
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000401:mortality; D001408:Bacillus anthracis / Q000276:immunology / Q000472:pathogenicity; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology*; D007378:Interleukins / Q000097:blood / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000382:microbiology; D048371:MAP Kinase Kinase 3 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D050794:STAT1 Transcription Factor / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction / Q000502:physiology; D013154:Spleen / Q000276:immunology / Q000382:microbiology; D013171:Spores, Bacterial / Q000276:immunology; D015996:Survival Rate
chemical_list: D016898:Interferon-alpha; D007378:Interleukins; D050794:STAT1 Transcription Factor; C494080:Stat1 protein, mouse; D007371:Interferon-gamma; D048371:MAP Kinase Kinase 3; C482531:Map2k3 protein, mouse
references: Science. 1993 Mar 19;259(5102):1739-42
references: 8456300
references: Microb Pathog. 1989 Dec;7(6):421-8
references: 2516219
references: Cell. 1996 Feb 9;84(3):431-42
references: 8608597
references: Lancet. 1997 May 24;349(9064):1513-5
references: 9167461
references: J Immunol. 1998 Jan 1;160(1):284-92
references: 9551982
references: Science. 1998 May 1;280(5364):734-7
references: 9563949
references: Am J Respir Crit Care Med. 1998 Oct;158(4):1156-62
references: 9769275
references: Int J Tuberc Lung Dis. 1999 Mar;3(3):214-8
references: 10094322
references: EMBO J. 1999 Apr 1;18(7):1845-57
references: 10202148
references: J Biol Chem. 1999 Oct 15;274(42):30127-31
references: 10514501
references: EMBO J. 1999 Oct 15;18(20):5601-8
references: 10523304
references: J Biol Chem. 2005 Jul 1;280(26):24462-71
references: 15878863
references: Surg Infect (Larchmt). 2005 Winter;6(4):397-407
references: 16433604
references: J Infect Dis. 2006 Mar 15;193(6):829-40
references: 16479518
references: J Immunol. 2007 Mar 1;178(5):2646-50
references: 17312104
references: Infect Immun. 2007 Apr;75(4):1757-64
references: 17242059
references: FEBS Lett. 2002 Sep 11;527(1-3):211-5
references: 12220662
references: FEBS Lett. 1999 Nov 26;462(1-2):199-204
references: 10580119
references: Eur Cytokine Netw. 2000 Mar;11(1):99-104
references: 10705306
references: J Immunol. 2000 Aug 15;165(4):2028-39
references: 10925286
references: Immunity. 2000 Nov;13(5):715-25
references: 11114383
references: J Immunol. 2001 Jan 1;166(1):466-72
references: 11123325
references: Proc Natl Acad Sci U S A. 2001 May 8;98(10):5752-7
references: 11320211
references: Annu Rev Microbiol. 2001;55:647-71
references: 11544370
references: JAMA. 2002 May 1;287(17):2236-52
references: 11980524
references: J Immunol. 2002 Jul 1;169(1):366-74
references: 12077266
references: Emerg Infect Dis. 2002 Oct;8(10):1019-28
references: 12396909
references: Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):375-80
references: 12676806
references: J Immunol. 2004 Jan 15;172(2):747-51
references: 14707042
references: Tohoku J Exp Med. 2004 Jan;202(1):41-50
references: 14738323
references: Infect Immun. 2004 Mar;72(3):1291-7
references: 14977930
references: Infect Immun. 2004 Aug;72(8):4801-9
references: 15271942
references: Infect Immun. 1989 Jun;57(6):1800-8
references: 2498208
references: Science. 1993 Mar 19;259(5102):1742-5
references: 8456301